EyePoint Pharmaceuticals, Inc. (EYPT) has a consensus analyst rating of Buy, based on 18 analysts covering the stock. Of those, 16 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for EYPT is $37.50, representing a +161.5% upside from the current price of $14.34. Price targets range from a low of $36.00 to a high of $39.00.
